SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1474 4465 OR L773:1474 4422 ;srt2:(2005-2009)"

Sökning: L773:1474 4465 OR L773:1474 4422 > (2005-2009)

  • Resultat 11-20 av 36
  • Föregående 1[2]34Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
11.
  • Vellas, Bruno, et al. (författare)
  • Disease-modifying trials in Alzheimer's disease : a European task force consensus.
  • 2007
  • Ingår i: Lancet Neurology. - 1474-4422 .- 1474-4465. ; 6:1, s. 56-62
  • Forskningsöversikt (refereegranskat)abstract
    • After symptomatic treatments, the new target for therapeutic approaches in Alzheimer's disease is the development of disease-modifying drugs. The concept of disease modification in Alzheimer's disease is controversial and the design of these trials raises many questions. Which populations should be studied? For how long? With which principal and secondary endpoints? Are surrogate markers available? Here, we present a European consensus on disease-modifying trials in Alzheimer's disease, agreed under the auspices of the European Alzheimer's Disease Consortium and based on the European perspective of the concept of disease modification, study designs, the role for biomarkers, risk benefit, and pharmacoeconomic issues.
  •  
12.
  • Vellas, Bruno, et al. (författare)
  • Endpoints for trials in Alzheimer's disease : a European task force consensus.
  • 2008
  • Ingår i: Lancet Neurology. - 1474-4422 .- 1474-4465. ; 7:5, s. 436-450
  • Forskningsöversikt (refereegranskat)abstract
    • Harmful consequences in health status caused by disease are referred to as outcomes, and in clinical studies the measures of these outcomes are called endpoints. A major challenge when deciding on endpoints is to represent the outcomes of interest accurately, and the accuracy of such representation is assessed through validation. Complex diseases like Alzheimer's disease have many different and interdependent outcomes. We present a consensus for endpoints to be used in clinical trials in Alzheimer's disease, agreed by a European task force under the auspices of the European Alzheimer Disease Consortium. We suggest suitable endpoints for primary and secondary prevention trials, for symptomatic and disease-modifying trials in very early, mild, and moderate Alzheimer's disease, and for trials in severe Alzheimer's disease. A clear and consensual definition of endpoints is crucial for the success of further clinical trials in the field and will allow comparison of data across studies.
  •  
13.
  •  
14.
  • van der Burg, Jorien Mm, et al. (författare)
  • Beyond the brain: widespread pathology in Huntington's disease.
  • 2009
  • Ingår i: Lancet Neurology. - 1474-4465. ; 8:8, s. 765-774
  • Tidskriftsartikel (refereegranskat)abstract
    • Huntington's disease (HD) is an inherited neurodegenerative disorder caused by a polyglutamine stretch in the huntingtin protein. Today, more than 15 years after the genetic defect underlying HD was discovered, the pathogenesis is still not well understood and there is no adequate treatment. Research into this disorder has conventionally focused on neurological symptoms and brain pathology, particularly neurodegeneration in the basal ganglia and cerebral cortex. Mutant huntingtin is, however, ubiquitously expressed throughout the body. Indeed, contrary to earlier thinking, HD is associated with abnormalities in peripheral tissues. These abnormal changes are not all secondary to brain dysfunction, but most seem to be directly caused by expression of mutant huntingtin in peripheral tissues. In this article, we highlight this emerging field of research and how it might affect our understanding of the pathogenesis of this disease, the development of novel biomarkers of disease progression, and the identification of new potential treatments.
  •  
15.
  •  
16.
  •  
17.
  •  
18.
  •  
19.
  •  
20.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 11-20 av 36
  • Föregående 1[2]34Nästa

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy